06 February 2024 | Tuesday | News
Image Source : Public Domain
• QIAstat-Dx solutions will enable efficient and timely patient-centered care for communicable diseases
The QIAstat-Dx system is designed for use in laboratories and employs cost-efficient, single-use cartridges with all reagents on board and built-in sample processing. Utilizing multiplex real-time PCR, it detects and differentiates between multiple pathogens. QIAstat-Dx additionally provides easy-to-view cycle threshold (Ct) values and amplification curves that can offer additional insights not available with end-point PCR or other techniques.
“QIAGEN’s QIAstat-Dx panels provide medical professionals in India with a powerful tool for rapid and accurate diagnosis of infectious diseases, improving patient outcomes and reducing the burden on healthcare systems,” said Manoj Jagathmohan, Director & Head, India and South Asia at QIAGEN .
The QIAstat-Dx Meningitis/Encephalitis Panel analyzes 15 viral, bacterial and fungal pathogens in patients with suspected central nervous system infections simultaneously and provides results in just 80 minutes, enabling clinicians to select appropriate therapies in a timely manner. The test boasts high sensitivity and specificity, addressing an urgent need for rapid and reliable diagnosis of these life-threatening infections.
The QIAstat-Dx Gastrointestinal Panel 2 can identify 22 clinically relevant bacterial, viral, and parasitic pathogens that cause most GI infections in about an hour. This panel offers significant advantages over traditional microbiological testing, which often requires samples to be incubated for at least 24 hours and up to 10 days.
The QIAstat-Dx Respiratory SARS-CoV-2 Panel can detect 23 viral and bacterial pathogens causing respiratory infections. This panel is particularly relevant in India, where respiratory diseases are among the most prevalent communicable diseases.
QIAstat-Dx is available in two formats: The QIAstat-Dx version that brings together up to four Analytical Modules into one integrated system, and the QIAstat-Dx Rise higher-capacity version that provides comprehensive testing for up to 160 tests per day using eight Analytical Modules.
With a QIAstat-Dx Connectivity plan, QIAstat-Dx connects to the QIAsphere cloud-based platform that provides remote monitoring of the instruments and test status, allowing customers to receive push notifications on their personal devices. It can monitor an unlimited number of instruments across different hospitals or satellite labs, reducing system downtime and enabling fast and accurate syndromic testing. Connectivity is achieved through the Qbase hub, which can be connected to QIAstat-Dx in minimal time through hospitals’ LAN or Wi-Fi networks, ensuring sensitive patient data remains within the hospital network.
QIAstat-Dx solutions and syndromic tests to support diagnosing diseases are available in more than 100 countries worldwide. More than 3,500 cumulative systems were installed worldwide at the end of 2022.
Most Read
Bio Jobs
News
Editor Picks